Nongenotoxic Apoptosis Inducers Do Not Produce Misleading Positive Results in the TK6 Cell-Based GADD45a-GFP Genotoxicity Assay
Open Access
- 5 April 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 128 (1) , 79-91
Abstract
The in vitro mammalian genotoxicity tests identify some carcinogens not identified by the bacterial Ames test. However, historically they have produced rather more misleading predictions of carcinogenicity than the Ames test. This liability has been reduced in pharmaceutical testing by lowering the top-testing dose and rejecting data from excessively toxic doses. It also stimulated the development of new assays with inherently higher specificity. Among these, the GADD45a-GFP assay has been recognized as a maturing technology by the International Life Sciences Institute Health and Environmental Sciences Institute In Vitro Genetic Toxicity Emerging Technologies and New Strategies workgroup and has been concluded to be suitable for inclusion in a battery of high throughput screening by the U.K. Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment. GADD45a is induced by compounds that cause damage to or missegregation of chromosomes, and is implicated in the stimulation of repair or apoptosis where damage is overwhelming. It is therefore important to understand whether this causes a liability in the assay to produce misleading positives for nongenotoxic inducers of apoptosis. Compounds hypothesized to stimulate apoptosis in the GADD45a-GFP assay or to induce GADD45a in the absence of genotoxic stress, such as p53 activators, NF-κB and Bcl-2 inhibitors were selected. Apoptosis induction was monitored using Annexin V binding and caspase 3/7 activation assays. The majority of compounds tested were negative in the GADD45a-GFP assay. The few that generated positive data were also found positive in concurrent comet assay and/or micronucleus tests. The data presented here demonstrate that the GADD45a-GFP assay is not vulnerable to the generation of misleading positive results by apoptosis inducers.Keywords
This publication has 44 references indexed in Scilit:
- Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1Cell Death & Disease, 2011
- Autophagy in the Cellular Energetic BalanceCell Metabolism, 2011
- A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiationBMC Cancer, 2011
- Genotoxic effect of 6-gingerol on human hepatoma G2 cellsChemico-Biological Interactions, 2010
- DNA damage response to the Mdm2 inhibitor Nutlin-3Biochemical Pharmacology, 2010
- Co-Inhibition of BCL-W and BCL2 Restores Antiestrogen Sensitivity through BECN1 and Promotes an Autophagy-Associated NecrosisPLOS ONE, 2010
- Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosisProceedings of the National Academy of Sciences, 2007
- In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicityMutation Research - Genetic Toxicology and Environmental Mutagenesis, 2007
- Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumorsNature Medicine, 2004
- Inhibitory effect of Bcl-2 on p53-mediated transactivation following genotoxic stressOncogene, 1999